ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

The Oncological Influences of Pre- and Post-Transplant Sustained Viral Response in Liver Transplant for Hepatocellular Carcinoma

K. Sasaki1, S. Kimura2, K. Tomiyama3, Y. Bekki4, M. Murray3, P. Huang3, M. Fruscione2, A. Moro5, C. Kwon6

1Stanford University, Stanford, CA, 2Massachusetts General Hospital, Boston, MA, 3University of Rochester, Rochester, NY, 4Mount Sinai Medical Center, New York, NY, 5University of South Florida, Tampa, FL, 6Cleveland Clinic, Cleveland, OH

Meeting: 2022 American Transplant Congress

Abstract number: 1099

Keywords: Hepatitis C, Hepatocellular carcinoma, Liver transplantation

Topic: Clinical Science » Liver » 56 - Liver: Hepatocellular Carcinoma and Other Malignancies

Session Information

Session Name: Liver: Hepatocellular Carcinoma and Other Malignancies

Session Type: Poster Abstract

Date: Sunday, June 5, 2022

Session Time: 7:00pm-8:00pm

 Presentation Time: 7:00pm-8:00pm

Location: Hynes Halls C & D

*Purpose: Chronic hepatitis C infection (HCV) is one of the most common causes of hepatocellular carcinoma. After emerging direct-acting agents (DAA), the success rate of sustained viral response (SVR) is approximately 95%. Although, the eradication of HCV is a feasible option and survival benefit is obvious for liver transplant (LT) patients, the oncological benefit of SVR has not been fully elucidated to date. Especially, achieving SVR is beneficial to post-LT overall survival, which affects estimating the oncological influences of SVR in LT for HCC. This study aimed to investigate the influences of pre-and post-transplant SVR on tumor recurrence using a competing risk model.

*Methods: This was a multicenter study, which included 546 adult HCV patients with HCC who underwent LT between 2002-2020. The oncological benefits of achieving SVR were evaluated using the Fine and Gray competing risk model (event: recurrence, competing risk: non-cancer-related death). The oncological risk was defined as RETREAT score >3.

*Results: Of 546 HCV patients, 145 patients achieved SVR before transplant, and 228 patients achieved SVR after transplant. The cumulative incidence curves of recurrence and non-cancer-related death were shown (Figure). Achieving SVR reduced the risk of both HCC recurrence and non-cancer-related death compared to patients without SVR. The competing risk regression analyses showed achieving SVR reduced 24% (p=0.02) of recurrence risk and 38 % risk of non-cancer-related death. Of patients who achieved SVR, there was no significant difference according to the timing of achieving SVR (postoperative SVR; HR 0.67 (0.35-1.26), p=0.21). Interestingly, the HR of postoperative SVR was 0.50 (p=0.15) in low oncological risk patients and was 1.3 in the high oncological risk cohort (p=0.56).

*Conclusions: Achieving SVR reduces both cancer and non-cancer risk. The prognostic influence of SVR timing (pre-LT or post LT) is still controversial and possibly differ according to the oncological risk of recurrence.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Sasaki K, Kimura S, Tomiyama K, Bekki Y, Murray M, Huang P, Fruscione M, Moro A, Kwon C. The Oncological Influences of Pre- and Post-Transplant Sustained Viral Response in Liver Transplant for Hepatocellular Carcinoma [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/the-oncological-influences-of-pre-and-post-transplant-sustained-viral-response-in-liver-transplant-for-hepatocellular-carcinoma/. Accessed June 7, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences